


ProQR Therapeutics N.V. (Mon, Apr 29, 2024)

Sell candidate since Apr 29, 2024

StockInvest.us
Gyneju st. 14, "ROCKIT"
Vilnius, LT-01109
Lithuania



score: **-1.45**
#12693/ 30074

Trend: Hold
MV Long: Sell
MV Short: Sell
Pivot: Buy
Volume: Buy
MACD: Sell

Tech commentaries:

The **ProQR Therapeutics N.V.** stock price gained **1.55%** on the last trading day (Monday, 29th Apr 2024), rising from **\$1.94** to **\$1.97**. During the last trading day the stock fluctuated **6.22%** from a day low at **\$1.93** to a day high of **\$2.05**. The price has fallen in 6 of the last 10 days and is down by **-3.67%** for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, **254 thousand** more shares were traded than the day before. In total, **304 thousand** shares were bought and sold for approximately **\$598.02 thousand**.

The stock is at the lower part of a very wide and horizontal trend in the short term, and normally this may pose a good buying opportunity, though a breakdown through the bottom trend line at **\$1.86** will give a strong sell signal and a trend shift may be expected. Given the current horizontal trend, you can expect **ProQR Therapeutics N.V.** stock with a 90% probability to be traded between **\$1.88** and **\$2.60** at the end of this 3-month period. A break of a horizontal trend is often followed by a large increase in the volume, and stocks seldom manage to go directly from the bottom of a trend up to the top. Stocks turning up in the middle of a horizontal trend are therefore considered to be potential runners.

A buy signal was issued from a pivot bottom point on **Thursday, April 18, 2024**, and so far it has risen 5.91%. Further rise is indicated until a new top pivot has been found. **ProQR Therapeutics N.V.** has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation. Higher liquidity also reduces the general risk. Some negative signals were issued as well, and these may have some influence on the near short-term development. The **ProQR Therapeutics N.V.** stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at **\$1.98** and **\$2.19**. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

ProQR Therapeutics N.V. finds support from accumulated volume at **\$1.95** and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the stock meets some resistance from accumulated volume at **\$2.17**, **\$2.20** and **\$2.33**.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved **\$0.120** between high and low, or **6.22%**. For the last week, the stock has had daily average volatility of **5.98%**.

ProQR Therapeutics N.V. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Hold/Accumulate to a Sell candidate.

Risk: High

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.